|Articles|February 3, 2022

Vitamin D Deficiency Increases Risk of Severe or Fatal COVID-19

Author(s)Nina Cosdon

COVID-19 patients who were vitamin D deficient before infection were 14 times more likely to have severe or fatal COVID-19 disease.

Vitamin D is crucial to maintain bone health and facilitate immune system function. Early in the pandemic, health officials encouraged the public to take vitamin D supplements to boost immune response and potentially protect against COVID-19.

Now, studies are increasingly linking low vitamin D levels to an elevated risk of COVID-19 infection and death. One study, published today in PLOS ONE, is among the first to analyze vitamin D levels prior to COVID-19 infection.

Jointly led by Bar-Ilan University and Galilee Medical Center, the study looked for any correlation between pre-infection serum 25-hydroxyvitamin D (25(OH)D) level and COVID-19 severity and mortality. Investigators analyzed hospital records of individuals admitted to the Galilee Medical Center in Nahariya, Israel from April 7, 2020-February 4, 2021. Included subjects had a positive PCR COVID-19 test and 25(OH)D levels documented 14-730 days prior to their infection.

The investigators grouped patients by disease severity and level of 25(OH)D. Vitamin D levels were categorized as deficient, insufficient, adequate, or high-normal. They determined COVID-19 disease severity using multivariable regression analysis. Utilizing a cosinor model, the investigators isolated the influence of a sinusoidal pattern of seasonal 25(OH)D fluctuations.

Of the 1176 patients included in the study, 253 had a record of their 25(OH)D level before COVID-19 infection. Patients with a vitamin D deficiency, defined as < 20 ng/mL, were 14 times more likely to have severe or fatal COVID-19 disease than patients with 25(OH)D ≥ 40 ng/mL.

Overall, a low vitamin D status was present in 87.4% of patients with severe or critical COVID-19, but only 34.3% of patients with mild to moderate disease were vitamin D deficient. Mortality among patients with sufficient vitamin D was 2.3%, but 25.6% in vitamin D deficient patients.

"This study contributes to a continually evolving body of evidence suggesting that a patient's history of vitamin D deficiency is a predictive risk factor associated with poorer COVID-19 clinical disease course and mortality," said study co-author Michael Edelstein a professor at Bar-Ilan University. "It is still unclear why certain individuals suffer severe consequences of COVID-19 infection while others don’t. Our finding adds a new dimension to solving this puzzle."


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.